• LAST PRICE
    2.9390
  • TODAY'S CHANGE (%)
    Trending Up0.1890 (6.8727%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    2.9630 / 2.7500
  • Day Range
    Low 2.9390
    High 2.9630
  • 52 Week Range
    Low 0.1600
    High 8.9700
  • Volume
    316
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 2.963
TimeVolumeKRBP
02:42 ET1002.939
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesKRBP
Kiromic Biopharma Inc
3.8M
-0.1x
---
United StatesGOVX
GeoVax Labs Inc
3.7M
-0.1x
---
United StatesCMND
Clearmind Medicine Inc
3.9M
0.0x
---
United StatesCPMV
Mosaic Immunoengineering Inc
4.0M
-3.2x
---
United StatesRNAZ
Transcode Therapeutics Inc
3.6M
0.0x
---
United StatesBTAX
Biostax Corp
3.9M
-2.5x
---
As of 2024-04-14

Company Information

Kiromic BioPharma, Inc. is a clinical-stage fully integrated biotherapeutics company using its DIAMOND artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. The Company is developing multi-indication allogeneic T cell therapies that exploit the natural potency of Gamma Delta T cells (GDTs) to target solid tumors. It has three product candidates: Deltacel non-engineered GDTs, expanded and activated with technology, Procel GDTs engineered with a PD-1 switch receptor and Isocel GDTs engineered with an anti-Mesothelin isoform 2 Chimeric Antigen Receptor. Its Procel and Isocel product candidates consist of allogeneic, engineered, off-the-shelf GDT cells and they are in the preclinical development stage. Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. It also has new technologies in development to support its end-to-end approach.

Contact Information

Headquarters
7707 Fannin St., Suite 140HOUSTON, TX, United States 77054
Phone
832-968-4888
Fax
302-655-5049

Executives

Non-Executive Independent Chairman of the Board
Michael Nagel
Interim Chief Executive Officer, Director
Pietro Bersani
Interim Chief Financial Officer and Principal Accounting
Brian Hungerford
Interim Chief Operating Officer, Chief Scientific Officer
Leonardo Mirandola
Chief of Staff
Scott Dahlbeck

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.8M
Revenue (TTM)
$0.00
Shares Outstanding
1.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.99
EPS
$-29.21
Book Value
$-8.91
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.